Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

BACKGROUND & AIMS: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. METHODS: The REACH-B, aMAP,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Young-Suk, Chan, Henry L.Y., Ahn, Sang Hoon, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry L.A., Pan, Calvin Q., Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Shalimar, Brunetto, Maurizia, Hui, Aric Josun, Chang, Ting-Tsung, Lim, Seng Gee, Abramov, Frida, Flaherty, John F., Wang, Hongyuan, Yee, Leland J., Kao, Jia-Horng, Gane, Edward, Hou, Jinlin, Buti, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522903/
https://www.ncbi.nlm.nih.gov/pubmed/37771546
http://dx.doi.org/10.1016/j.jhepr.2023.100847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522903/
https://www.ncbi.nlm.nih.gov/pubmed/37771546
http://dx.doi.org/10.1016/j.jhepr.2023.100847

Ejemplares similares